Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 252, Issue 4, 2014, Pages 633-640

  Schaap Fogler, Michal ^a   Amer, Radgonde ^b   Friling, Ronit ^c,d   Priel, Ethan ^e   Kramer, Michal ^a,c,d  

^a Department of Ophthalmology Rabin Medical Center Beilinson Campus ^*  (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e Mor Institute for Medical Data   (Israel)

Author keywords

Anti TNF ; Cystoid macular edema; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID;

ADULT; ARTICLE; CENTRAL MACULAR THICKNESS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; SCHOOL CHILD; TERTIARY CARE CENTER; UVEITIS; VISUAL ACUITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; HUMANS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; RECURRENCE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VISUAL ACUITY; YOUNG ADULT;

EID: 84897570078     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-013-2552-8     Document Type: Article

References (39)

1. Curnow SJ, Murray PI (2006) Inflammatory mediators of uveitis: cytokines and chemokines. Curr Opin Ophthalmol 17:532-537
2. Ouchi M, West K, Crabb JW, Kinoshita S, Kamei M (2005) Proteomic analysis of vitreous from diabetic macular edema. Exp Eye Res 81:176-182
3. Curnow SJ, Falciani F, Durrani OM, Cheung CM, Ross EJ, Wloka K, Rauz S, Wallace GR, Salmon M, Murray PI (2005) Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Invest Ophthalmol Vis Sci 46:4251-4259
4. van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD (2006) Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol 142:192-194
5. van Laar JA, van Hagen PM (2006) Cytokines in uveitis. Clin Med Res 4:248-249
6. De Vos AF, Hoekzema R, Kijlstra A (1992) Cytokines and uveitis, a review. Curr Eye Res 11(6):581-597
7. Ossewaarde-van Norel A, Rothova A (2011) Clinical review: update on treatment of inflammatory macular edema. Ocul Immunol Inflamm 19(1):75-83
8. Roesel M, Ruttig A, Schumacher C, Heinz C, Heiligenhaus A (2011) Risk factors for the development of macular edema in noninfectious uveitis. Eur J Ophthalmol 21(5):625-630
9. Sreekantam S, Denniston AK, Murray PI (2011) Survey of expert practice and perceptions of the supporting clinical evidence for the management of uveitis-related cataract and cystoid macular oedema. Ocul Immunol Inflamm 19(5):353-357
10. Lardenoye CW, van Kooij B, Rothova A (2006) Impact of macular edema on visual acuity in uveitis. Ophthalmology 113(8):1446-1449
11. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80(4):332-336
12. Rothova A (2002) Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 10(4):239-246
13. Papadaki T, Zacharopoulos I, Iaccheri B, Fiore T, Foster CS (2005) Somatostatin for uveitic cystoid macular edema (CME). Ocul Immunol Inflamm 13(6):469-470
14. van Kooij B, Rothova A, de Vries P (2006) The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm 14(2):73-85
15. Gutfleisch M, Spital G, Mingels A, Pauleikhoff D, Lommatzsch A, Heiligenhaus A (2007) Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. Br J Ophthalmol 91(3):345-348
16. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SMS, Yocum D (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130(4):492-513
17. Gulati N, Forooghian F, Lieberman R, Jabs DA (2011) Vascular endothelial growth factor inhibition in uveitis: a systematic review. Br J Ophthalmol 95(2):162-165, Epub 2010 May 21
18. Bae JH, Lee CS, Lee SC (2011) Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 31(1):111-118
19. Habot-Wilner Z, Sallam A, Pacheco PA, Do HH, McCluskey P, Lightman S (2010) Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema. Eur J Ophthalmol 21(S6):56-61
20. Santos Lacomba M, Marcos Martín C, Gallardo Galaera JM, Gómez Vidal MA, Collantes Estévez E, Ramírez Chamond R, Omar M (2001) Aqueous humor and serum tumor necrosis factor-Alpha in clinical uveitis. Ophthalmic Res 33:251-255
21. Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Estévez E (2004) Tumour necrosis factor-Alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 20(2):155-157
22. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D (2004) Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111(2):352-356
23. Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, Suarez-de-Figueroa M, Rio-Pardo MJ, Fernandez-Cid C, Fonollosa A, Blanco R, Garcia-Aparicio AM, Benitez-Del-Castillo JM, Olea JL, Arevalo JF (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119(8):1575-1581
24. Murphy CC, Greiner K, Plskova J, Duncan L, Frost A, Isaacs JD, Rebello P, Waldmann H, Hale G, Forrester JV, Dick AD (2004) Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 122(6):845-851
25. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP (2004) Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 138(4):648-650
26. Diaz-Llopis M, García-Delpech S, Salom D, Udaondo P, Hernández-Garfella M, Bosch-Morell F, Quijada A, Romero FJ (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(3):351-361
27. Farvardin M, Afarid M, Mehryar M, Hosseini H (2010) Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 30(9):1530-1535
28. Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P (2010) Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 117(8):1612-1616
29. Olivieri I, Latanza L, Siringo S, Peruz G, Di Iorio V (2008) Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete. J Rheumatol 35:930-932
30. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M (2012) Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 250(5):713-720
31. Calleja S, Cordero-Coma M, Rodriguez E, Llorente M, Franco M, Ruiz de Morales JG (2012) Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(-) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study. Eye (Lond) 26(3):468-477
32. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL (2009) Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 116(4):797-801
33. Campochiaro PA, Hafiz G, Channa R, Shah SM, Nguyen QD, Ying H, Do DV, Zimmer-Galler I, Solomon SD, Sung JU, Syed B (2010) Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology 117(12):2387-2394, e1-5
34. Stewart MW (2012) Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. Curr Diabetes Rev 8(4):237-246
35. Deuter CM, Kötter I, Günaydin I, Stübiger N, Doycheva DG, Zierhut M (2009) Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 93(7):906-913
36. Adán A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, Sanmartí R (2010) Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. Int Ophthalmol 30(5):577-581
37. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M (2010) Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol 94:284-288
38. Lee RWJ, Dick AD (2010) Treat early and embrace the evidence in favour of anti-TNF-A therapy for Behcet's uveitis. Br J Ophthalmol 94(3):269-270
39. Olivieri I, Padula A, Leccese P, D'Angelo S, Giasi V (2009) Long-lasting remission of severe Behçet's disease after the end of infliximab therapy. J Rheumatol 36(4):855